导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.70% | 862/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -3.88% | 2044/5421 |
| 近一季 | -3.75% | 1457/5209 |
| 近半年 | -3.00% | 2091/4920 |
| 近一年 | 10.47% | 997/4366 |
| 近两年 | 67.47% | 1025/2954 |
| 近三年 | 36.88% | 803/2253 |
| 成立以来 | 35.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.16% 796/4961 |
13.78% 1944/5312 |
- - |
- - |
| 2025 | 23.55% 1865/4813 |
2.43% 1375/3635 |
1.71% 2214/4076 |
18.56% 2283/4524 |
0.03% 2274/4813 |
| 2024 | 6.83% 1717/3463 |
-1.17% 1189/2808 |
-4.99% 1611/3014 |
14.17% 2036/3129 |
-0.35% 1393/3463 |
| 2023 | -3.13% 630/2656 |
8.94% 436/2280 |
-4.36% 1150/2385 |
-3.84% 1002/2515 |
-3.32% 655/2655 |
| 2022 | -20.36% 966/2207 |
-10.93% 458/1919 |
0.36% 1556/2016 |
-12.46% 707/2113 |
1.78% 1145/2208 |
| 2021 | 29.07% 76/1822 |
4.14% 160/1255 |
16.12% 210/1330 |
4.31% 367/1466 |
2.33% 619/1822 |
| 2020 | - - |
- - |
- - |
- - |
-0.33% 1071/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 上银中证500指数增强型C VS. 长安沪深300非周期A(740101) |